Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | CALML3 | P27482 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6767666 | 0.85 | MAOB (0.40) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL5378623 | 0.81 | MAOA (0.44) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL5845905 | 0.81 | MAOA (0.48) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL4884934 | 0.81 | MAOA (0.43) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL5730354 | 0.81 | MAOA (0.48) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL5472893 | 0.81 | MAOB (0.62) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL5323611 | 0.81 | MAOA (0.47) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL6506664 | 0.80 | F10 (0.54) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL5725958 | 0.80 | MAOA (0.52) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL4884103 | 0.79 | MAOA (0.46) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869965-B2 | Such as 2-methylpropyl-(4-bromo-3-fluorophenyl)carbamate | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-22 | — | — | US | claimed |
| US-6689769-B2 | BACTERICIDES | PHARMACIA & UPJOHN COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030013737-A1 | Antimicrobial quinolone derivatives and use of the same to treat bacterial infections | PHARMACIA & UPJOHN COMPANY | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013737-A1 | Antimicrobial quinolone derivatives and use of the same to treat bacterial infections | BRD7, BRD1, NQO2 | MAOA 2041/4885CALML3 2894/4885MAOB 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.